These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 38115965)
1. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study. Kirsebom FCM; Stowe J; Lopez Bernal J; Allen A; Andrews N J Infect; 2024 Jul; 89(1):106177. PubMed ID: 38719110 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England. Kirsebom FCM; Andrews N; Stowe J; Dabrera G; Ramsay M; Lopez Bernal J EClinicalMedicine; 2024 May; 71():102587. PubMed ID: 38618208 [TBL] [Abstract][Full Text] [Related]
6. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440 [TBL] [Abstract][Full Text] [Related]
7. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023. Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051 [TBL] [Abstract][Full Text] [Related]
8. Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study. Aggarwal NR; Beaty LE; Bennett TD; Fish LE; Jacobs JR; Mayer DA; Molina KC; Peers JL; Richardson DB; Russell S; Varela A; Webb BJ; Wynia MK; Xiao M; Carlson NE; Ginde AA Lancet Reg Health Am; 2024 Mar; 31():100693. PubMed ID: 38500962 [TBL] [Abstract][Full Text] [Related]
9. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations. Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39107255 [TBL] [Abstract][Full Text] [Related]
11. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster. Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J medRxiv; 2024 Jun; ():. PubMed ID: 38883802 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada. Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Fafard J; Gilca R; Talbot D; Ouakki M; Febriani Y; Deceuninck G; De Wals P; De Serres G Lancet Healthy Longev; 2023 Aug; 4(8):e409-e420. PubMed ID: 37459879 [TBL] [Abstract][Full Text] [Related]
14. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon. Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064 [TBL] [Abstract][Full Text] [Related]
15. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron. Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390 [TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant. Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876 [TBL] [Abstract][Full Text] [Related]
17. Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023. Poukka E; Perälä J; Nohynek H; Goebeler S; Auranen K; Leino T; Baum U Euro Surveill; 2024 Sep; 29(37):. PubMed ID: 39268649 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. Shrestha NK; Burke PC; Nowacki AS; Simon JF; Hagen A; Gordon SM Open Forum Infect Dis; 2023 Jun; 10(6):ofad209. PubMed ID: 37274183 [TBL] [Abstract][Full Text] [Related]
19. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500 [TBL] [Abstract][Full Text] [Related]
20. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]